Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARVN vs DNLI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ARVN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–5 Matrix Metrics)
ARVN Overall Winner
6-Pillar Tally: ARVN 5 – 0 DNLI (1 Tie)
Matrix Metrics: ARVN 5 – 5 DNLI
As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Denali Therapeutics Inc. (DNLI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.78 (17.9x Forward P/E, -10.1% operating margin), whereas DNLI carries 55.5/100 (HOLD) at $18.33 (N/M Forward P/E, -2481.1% operating margin).
- Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. ARVN 52.9/100 HOLD), ARVN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-10.1% vs. -2481.1% operating margin) and revenue trajectory (-98.8% vs. -100.0% YoY).
- Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ARVN vs DNLI
ARVN
Head-to-Head Winner
Arvinas, Inc
$6.78
-0.59% 1D
Market Cap
$449.9M
TTM Revenue
$275M
Forward P/E
17.9x
Beta / 30D Vol
1.40β · 66% Vol
Unified Composite Score
52.9
HOLD
Tech 54.0
Fund 59.0
Flow 71.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
DNLI
Denali Therapeutics Inc. Common Stock
$18.33
-2.19% 1D
Market Cap
$3.0B
TTM Revenue
$21M
Forward P/E
N/M
Beta / 30D Vol
1.36β · 48% Vol
Unified Composite Score
55.5
HOLD
Tech 44.0
Fund 55.0
Flow 66.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ARVN 5 – 0 DNLI)
1. Valuation Multiples
ARVN
Forward P/E
17.9x
N/M
Trailing P/E
17.9x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
1.3x
138.2x
2. Growth & Scale
ARVN
Revenue Growth (YoY)
-98.8%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$275M
$21M
Market Cap
$449.9M
$3.0B
3. Profitability & Quality
ARVN
Gross Margin
96.7%
N/A
Operating Margin
-10.1%
-2481.1%
Net Profit Margin
-3.5%
0.0%
Return on Equity (ROE)
-1.8%
-33.9%
4. Balance Sheet & Cash Flow
ARVN
Cash Generation (TTM)
-$160M
-$486M
Cash Flow Margin
-58.0%
N/A
Net Cash / Leverage
$81M Net Cash
$73M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ARVN
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
108.7% (25th %ile)
78.2% (27th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
6.21x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ARVN (5) vs DNLI (5)| Institutional Metric | ARVN | DNLI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $449.9M | $3.0B | DNLI | |
| Trailing P/E Ratio | 17.9x | N/M | ARVN | |
| Forward P/E Ratio | 17.9x | N/M | ARVN | |
| Revenue Growth (YoY) | -98.8% | -100.0% | ARVN | |
| Operating Margin (TTM) | -10.1% | -2481.1% | ARVN | |
| Net Profit Margin | -3.5% | 0.0% | DNLI | |
| Return on Equity (ROE) | -1.8% | -33.9% | ARVN | |
| 52-Week Range Position | 6% ($6–$15) | 25% ($15–$27) | DNLI | |
| Beta / 30D Volatility | 1.40β · 66% Vol | 1.36β · 48% Vol | DNLI | |
| Unified Institutional Score | 52.9 / 100 (HOLD) | 55.5 / 100 (HOLD) | DNLI | |
| Trailing 12M Revenue (USD) | $275M | $21M | Scale | |
| Gross Profit Margin (TTM) | 96.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.3x EV/Rev | N/M PEG · 138.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$160M ($81M Net Cash) | -$486M ($73M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DNLI +6.82 pp
3M Horizon
DNLI +2.18 pp
6M Horizon
DNLI +22.4 pp
1Y Horizon
DNLI +39.88 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARVN Revenue | DNLI Revenue | ARVN Op. Margin | DNLI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | $130M | -306.3% | -35.9% | DNLI |
| FY2019 | $20M | $30M | -281.4% | -810.0% | ARVN |
| FY2020 | $20M | $340M | -554.1% | 18.7% | DNLI |
| FY2021 | $50M | $50M | -403.4% | -607.8% | ARVN |
| FY2022 | $130M | $110M | -200.3% | -324.3% | ARVN |
| FY2023 | $80M | $330M | -511.5% | -59.5% | DNLI |
| FY2024 | $260M | N/A | -95.0% | N/A | ARVN |
| FY2025 | $260M | N/A | -45.1% | N/A | ARVN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ARVN
BREAKDOWN
Current IV
108.7%
IV Percentile
25th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DNLI
BREAKDOWN
Current IV
78.2%
IV Percentile
27th %ile
Put/Call OI Skew
6.21x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact DNLI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ARVN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DNLI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ARVN vs DNLI Key Questions & Quantitative Answers
As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Denali Therapeutics Inc. (DNLI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARVN carries a Unified Composite Score of 52.9/100 (HOLD) at $6.78 (17.9x Forward P/E, -10.1% operating margin), whereas DNLI carries 55.5/100 (HOLD) at $18.33 (N/M Forward P/E, -2481.1% operating margin). Composite vs. Pillar Nuance: While DNLI currently prints a higher short-term Unified Composite Score (55.5/100 HOLD vs. ARVN 52.9/100 HOLD), ARVN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-10.1% vs. -2481.1% operating margin) and revenue trajectory (-98.8% vs. -100.0% YoY). Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile DNLI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with DNLI at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (N/A gross margin, -2481.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while DNLI shifted +153.8%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNLI.
ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas DNLI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 138.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus DNLI (-33.9% ROE) capital efficiency.
In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, DNLI carries 78.2% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 6.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DNLI vs ARVN · Reverse Pair
ARVN vs KYMR
· Sector Peer
ARVN vs RCUS
· Sector Peer
DNLI vs RARE
· Sector Peer
DNLI vs BBIO
· Sector Peer
DNLI vs RCUS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem